Systematic-Review-Drug-Efficiency-Dissertation-Sample-Work-Tutors-India
Idiopathic Pulmonary Fibrosis (IPF) as the name suggests is a progressive disorder with no known aetiology. It is characterised by the thickening of the alveoli due to scarring resulting in cough. It is known to primarily occur in older adults over 60 years of age. The findings of IPF have a known association of Usual Interstitial Pneumonia (UIP) (Raghu et al., 2011; Kawano-Dourado & Kairalla, 2013; Wells, 2013). It has been deemed that the prognosis is generally poor when UIP has been confirmed (King et al., 2001b). The median survival rate of IPF is 50%, typically around two years after diagnosis (Raghu et al., 2011; King et al., 2001b).
Idiopathic Pulmonary Fibrosis (IPF) as the name suggests is a progressive disorder with no known aetiology. It is characterised by the thickening of the alveoli due to scarring resulting in cough. It is known to primarily occur in older adults over 60 years of age. The findings of IPF have a known association of Usual Interstitial Pneumonia (UIP) (Raghu et al., 2011; Kawano-Dourado & Kairalla, 2013; Wells, 2013). It has been deemed that the prognosis is generally poor when UIP has been confirmed (King et al., 2001b). The median survival rate of IPF is 50%, typically around two years after diagnosis (Raghu et al., 2011; King et al., 2001b).
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
pulmonary fibrosis. The New England journal of medicine. [Online]. 367 (9). pp. 870;<br />
author reply 870-1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22931326.<br />
Jakubzick, C., Choi, E.S., Joshi, B.H., Keane, M.P., Kunkel, S.L., Puri, R.K. & Hogaboam,<br />
C.M. (2003). Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and<br />
IL-13-responsive cells. Journal of immunology (Baltimore, Md. : 1950). 171 (5). pp.<br />
2684–2693.<br />
Jankowich, M.D., Polsky, M., Klein, M. & Rounds, S. (2008). Heterogeneity in combined<br />
pulmonary fibrosis and emphysema. Respiration; international review of thoracic<br />
diseases. [Online]. 75 (4). pp. 411–7. Available from:<br />
http://www.ncbi.nlm.nih.gov/pubmed/17684315.<br />
Jegal, Y., Kim, D.S., Shim, T.S., Lim, C.-M., Do Lee, S., Koh, Y., Kim, W.S., Kim, W.D.,<br />
Lee, J.S., Travis, W.D., Kitaichi, M. & Colby, T. V (2005). Physiology is a stronger<br />
predictor of survival than pathology in fibrotic interstitial pneumonia. American journal<br />
of respiratory and critical care medicine. [Online]. 171 (6). pp. 639–44. Available from:<br />
http://www.ncbi.nlm.nih.gov/pubmed/15640368.<br />
Jiang, C., Huang, H., Liu, J., Wang, Y., Lu, Z. & Xu, Z. (2012). Adverse events of<br />
pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized<br />
controlled trials. PloS one. [Online]. 7 (10). pp. e47024. Available from:<br />
http://www.ncbi.nlm.nih.gov/pubmed/23056564.<br />
Johnston, C.J., Williams, J.P., Elder, A., Hernady, E. & Finkelstein, J.N. (2004).<br />
Inflammatory cell recruitment following thoracic irradiation. Experimental lung<br />
research. 30 (5). pp. 369–382.<br />
Johnston, C.J., Williams, J.P., Okunieff, P. & Finkelstein, J.N. (2002). Radiation-induced<br />
pulmonary fibrosis: examination of chemokine and chemokine receptor families.<br />
Radiation research. 157 (3). pp. 256–265.<br />
Kadikar, A., Maurer, J. & Kesten, S. (1997). The six-minute walk test: a guide to assessment<br />
for lung transplantation. The Journal of heart and lung transplantation : the official<br />
publication of the International Society for Heart Transplantation. [Online]. 16 (3). pp.<br />
© 2017-2018 All Rights Reserved, No part of this document should be modified/used without prior consent<br />
<strong>Tutors</strong> <strong>India</strong> - Your trusted mentor since 2001<br />
www.tutorindia.com I UK # +44-1143520021, info@tutorsindia.com<br />
Page 134 of 172
Change language